PCSK9 and familial hypercholesterolemia: Monoclonal antibodies against PCSK9 which were developed for the treatment of familial hypercholesterolemia have been shown to decrease free PCSK9 levels in the plasma almost immediately along with a significant drop in plasma LDL-cholesterol levels as early as 1 day after administration25.